Navigation Links
Biopure Announces 2007 Third Quarter Financial Results
Date:8/23/2007

CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced its financial results for the third fiscal quarter ended July 31, 2007. For the quarter, the company reported a net loss of $6.4 million, or $0.08 per common share, compared with a net loss of $6.6 million, or $0.16 per common share, for the corresponding period in 2006. Class A common shares outstanding on July 31, 2007 and 2006 were 77,960,126 and 41,789,370, respectively.

Revenues

Total revenues for the third quarter of 2007 were $550,000, including $470,000 from sales of the company's veterinary product Oxyglobin(R) and $58,000 from sales of Hemopure(R) in South Africa. Total revenues for the same period in 2006 were $396,000, including $312,000 from Oxyglobin sales and $1,000 from sales of Hemopure(R). The increase in Hemopure sales reflects the company's marketing efforts and increasing use of the product. Oxyglobin revenues increased during the third fiscal quarter of 2007 compared to 2006 due to a higher average selling price for product sold in the U.S.

Cost of revenues was $3.1 million for the third quarter of fiscal 2007, compared to $2.9 million for the same period in 2006. Cost of revenues includes costs of both Oxyglobin and Hemopure. The increase is mainly due to higher salaries expense and plant costs.

Expenses

Research and development expenses were $1.6 million for the third quarter of fiscal 2007 compared to $1.8 million during the same period in 2006. Expenses during the third fiscal quarter of 2006 include costs related to the marketing authorization application the company submitted to the United Kingdom regulatory authority in 2006, for which there are no comparable
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Clyde C Tuggle Senior Vice President at The Coca Cola Company Elected to CASA Board 52947 1Clyde C Tuggle Senior Vice President at The Coca Cola Company Elected to CASA Board 52947 2Clyde C Tuggle Senior Vice President at The Coca Cola Company Elected to CASA Board 52947 3Laureate Pharma Appoints Daniel E Leone as Vice President of Business Development 13233 1Laureate Pharma Appoints Daniel E Leone as Vice President of Business Development 13233 2Sunscreen on Your Feet 3F Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 52938 1Sunscreen on Your Feet 3F Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 52938 2
Other Medicine News:Health News:CuraGen Reports Third Quarter 2007 Financial Results 2Health News:CuraGen Reports Third Quarter 2007 Financial Results 3Health News:CuraGen Reports Third Quarter 2007 Financial Results 4Health News:CuraGen Reports Third Quarter 2007 Financial Results 5Health News:Luminex Corporation Reports Third Quarter 2007 Results 2Health News:Luminex Corporation Reports Third Quarter 2007 Results 3Health News:Luminex Corporation Reports Third Quarter 2007 Results 4Health News:Luminex Corporation Reports Third Quarter 2007 Results 5Health News:Luminex Corporation Reports Third Quarter 2007 Results 6Health News:Luminex Corporation Reports Third Quarter 2007 Results 7Health News:Luminex Corporation Reports Third Quarter 2007 Results 8Health News:Luminex Corporation Reports Third Quarter 2007 Results 9Health News:Luminex Corporation Reports Third Quarter 2007 Results 10Health News:Luminex Corporation Reports Third Quarter 2007 Results 11Health News:San Diego Wildfires Mental Health Fund 2Health News:San Diego Wildfires Mental Health Fund 3Health News:New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs 2Health News:New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs 3Health News:Shareholder Proposals and Director Nominations Due November 5, 2007 2Health News:Shareholder Proposals and Director Nominations Due November 5, 2007 3